Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06108050 · ClinicalTrials.gov registry record · Phase 1

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Jazz Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
177
Enrollment target
10
Study locations

NCT06108050 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 177 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06108050, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
177 participants
Enrollment target
10
Study locations

Study Summary

This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

Conditions Studied

Advanced Solid Tumor Metastatic Solid Tumor

Interventions

  • DRUG Pembrolizumab
  • DRUG JZP898

Study Locations (10)

California

  • California Cancer Associates for Research and Excellence - Encinitas
  • California Cancer Associates for Research and Excellence - Fresno

Texas

  • Texas Oncology - Baylor Charles A Sammons Cancer Center - Dallas
  • The University of Texas MD Anderson Cancer Center - Houston

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Florida

  • Florida Cancer Specialists - Orlando

North Carolina

  • Duke University Medical Center - Duke Cancer Institute - Durham

Pennsylvania

  • Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital - Philadelphia

Tennessee

  • SCRI Oncology Partners - Nashville

Virginia

  • Virginia Cancer Specialists - Fairfax

Trial Details

FieldValue
Enrollment Target 177 participants
Start Date 2023-11-07
Est. Completion 2028-05-31
Phase Phase 1

Sponsor

Jazz Pharmaceuticals

128 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06108050

The ClinicalTrials.gov registry entry for NCT06108050 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06108050 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Texas, Colorado.

Frequently Asked Questions

What is clinical trial NCT06108050 about?

NCT06108050 is a clinical study titled "JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors". This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

What is the current status of trial NCT06108050?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2023-11-07. Estimated completion is 2028-05-31.

What conditions does trial NCT06108050 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor.

What interventions are being tested in trial NCT06108050?

The interventions under investigation include: Pembrolizumab (DRUG), JZP898 (DRUG).

Who is sponsoring clinical trial NCT06108050?

This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06108050 being conducted?

This trial has 10 study locations across California, Colorado, Florida, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Metastatic Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.